/4875.T

4875.T Stock - MediciNova, Inc.

Q: What is the analyst price target for 4875.T?

Analyst price target information is not currently available for 4875.T.

Q: What is 4875.T's market cap?

Market capitalization information is not currently available for 4875.T.

Healthcare|Biotechnology|JPX

$210.00-2.78%

$6.00 (-2.78%) • Dec 24

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $231.00

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for 4875.T

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.48

52W High$350.00

52W Low$164.00

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	N/A	$1.00M	N/A	$4.04M	N/A
Gross Profit	N/A	$1.00M	N/A	$4.04M	N/A
Gross Margin	N/A	100.0%	N/A	100.0%	N/A
Operating Income	$-12,675,331	$-9,900,265	$-14,628,649	$-10,215,812	$-14,178,323
Net Income	$-11,049,549	$-8,571,516	$-14,069,083	$-10,134,252	$-13,853,897
Net Margin	N/A	-857.2%	N/A	-251.0%	N/A
EPS	$-0.23	$-0.17	$-0.29	$-0.21	$-0.31

Company Overview

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.

Visit Website

Earnings History & Surprises

4875.T

Beat Rate

82%

Last 17 quarters

Avg Surprise

+39.7%

EPS vs Estimate

Beats / Misses

14/2

1 met exactly

Latest EPS

$-9.33

Q4 2025

EPS Surprise History

Q1 24

+50.9%

$-5.91vs$-12.04

Q2 24

-14.7%

$-8.91vs$-7.77

Q3 24

+19.4%

$-7.09vs$-8.80

Q4 24

-7.8%

$-10.00vs$-9.28

Q1 25

+99.3%

$-0.06vs$-8.65

Q2 25

+99.7%

$-0.06vs$-17.64

Q3 25

+44.8%

$-9.69vs$-17.56

Q4 25

+50.0%

$-9.33vs$-18.66

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2026	May 11, 2026	—	—	—	—
Q1 2026	Feb 17, 2026	—	—	—	—
Q4 2025	Nov 13, 2025	$-18.66	$-9.33	+50.0%	✓ BEAT
Q3 2025	Aug 15, 2025	$-17.56	$-9.69	+44.8%	✓ BEAT
Q2 2025	May 13, 2025	$-17.64	$-0.06	+99.7%	✓ BEAT
Q1 2025	Feb 19, 2025	$-8.65	$-0.06	+99.3%	✓ BEAT
Q4 2024	Nov 14, 2024	$-9.28	$-10.00	-7.8%	✗ MISS
Q3 2024	Aug 9, 2024	$-8.80	$-7.09	+19.4%	✓ BEAT
Q2 2024	May 10, 2024	$-7.77	$-8.91	-14.7%	✗ MISS
Q1 2024	Feb 16, 2024	$-12.04	$-5.91	+50.9%	✓ BEAT
Q4 2023	Nov 10, 2023	$-12.08	$-1.45	+88.0%	✓ BEAT
Q3 2023	Aug 10, 2023	$-10.04	$-8.00	+20.3%	✓ BEAT
Q1 2023	Mar 31, 2023	$-9.30	$-7.90	+15.1%	✓ BEAT
Q4 2022	Dec 31, 2022	$-11.15	$-0.06	+99.5%	✓ BEAT
Q4 2022	Nov 11, 2022	$-0.09	$-0.07	+22.2%	✓ BEAT
Q3 2022	Aug 12, 2022	$-0.09	$-0.08	+11.1%	✓ BEAT
Q2 2022	May 13, 2022	$-0.09	—	—	—
Q1 2022	Feb 17, 2022	$-0.09	$-0.04	+55.6%	✓ BEAT
Q4 2021	Nov 12, 2021	$-0.09	$-0.07	+22.2%	✓ BEAT
Q3 2021	Aug 13, 2021	$-0.09	$-0.09	0.0%	= MET